• Geoffrey S Young, Vera Kimbrell, Ravi Seethamraju, and Ellen J Bubrick.
• Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
• J Neuroimaging. 2022 May 1; 32 (3): 377-388.

AbstractUltra-high-field 7.0 Tesla (T) MRI offers substantial gains in signal-to-noise ratio (SNR) over 3T and 1.5T, but for over two decades has remained a research tool, while 3T scanners have achieved widespread clinical use. This much slower translation of 7T relates to daunting technical challenges encountered in ultra-high-field human MR imaging. The recent introduction of United States Food and Drug Administration (FDA)-approved clinical 7T scanners promises to be a watershed for many 7T neuroimaging applications, including epilepsy imaging. The high SNR of 7T allows clinical imaging of fine neuroanatomic detail at unprecedented spatial resolution, helping with detection and differentiation of subtle, potentially treatable lesions undetectable or suboptimally assessed at 3T. The accompanying research paper reports our group's analysis of 7T MRI efficacy in epilepsy treatment planning. Here, we introduce the technical background and clinical approach we currently use, in order to assist clinical epileptologists and neuroimagers contemplating, creating, or referring patients to a clinical 7T epilepsy imaging service. We describe a tiered epilepsy imaging strategy and protocols designed to optimize 7T value and work around signal intensity variation and signal loss artifacts, which remain significant challenges to full exploitation of 7T clinical value. We describe FDA-approved techniques for mitigating these artifacts and briefly outline techniques currently under development, but not yet FDA approved. Finally, we discuss the major issues in 7T patient safety and toleration, outlining their physical causes and effects on workflow, and provide references to more comprehensive technical reviews for readers seeking greater technical detail.© 2022 American Society of Neuroimaging.

11 keywords...

hide…